Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H9N2O3S.Na.H2O |
Molecular Weight | 254.239 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1
InChI
InChIKey=IHCDKJZZFOUARO-UHFFFAOYSA-M
InChI=1S/C8H10N2O3S.Na.H2O/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;;/h2-5H,9H2,1H3,(H,10,11);;1H2/q;+1;/p-1
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C8H10N2O3S |
Molecular Weight | 214.242 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364668 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BLEPHAMIDE Approved UseBlephamide ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. Launch Date1961 |
|||
Curative | KLARON Approved UseKlaron Lotion is indicated in the topical treatment of acne vulgaris. Launch Date1996 |
PubMed
Title | Date | PubMed |
---|---|---|
Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. | 1990 Feb |
|
[The effective antibacterial spectrum of sulfacetamide]. | 1992 Mar |
|
Topical bactrim versus trimethoprim and sulfonamide against nocardia keratitis. | 2001 Mar |
|
Spectrophotometric determination of sulphacetamide. | 2002 Jul-Aug |
|
Studies on the influence of auxiliary substances on the physico-chemical characteristics of ophthalmic drugs. Part I. Studies on the influence of auxiliary substances on the critical micellar concentration of surfactants solutions in eye drops containing sulphacetamidum natricum. | 2002 Jul-Aug |
|
3-Aminophenol as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives. | 2003 Dec |
|
Liquid chromatography-fluorescence detection for simultaneous analysis of sulfonamide residues in honey. | 2003 Jun |
|
Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection. | 2004 Aug 20 |
|
Rosacea. An overview of diagnosis and management. | 2004 Dec |
|
The treatment of rosacea. | 2004 Jan |
|
The use of sulfur in dermatology. | 2004 Jul-Aug |
|
Sulfur/sodium sulfacetamide preparations. | 2004 Mar-Apr |
|
Rosac Cream With Sunscreens (sodium sulfacetamide 10% and sulfur 5%). | 2004 Mar-Apr |
|
Diagnosing and managing the patient with rosacea. | 2005 Apr |
|
Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. | 2005 Jun |
|
Simultaneous determination of 16 sulfonamides in honey by liquid chromatography/tandem mass spectrometry. | 2005 Sep-Oct |
|
Combination topical therapy in the treatment of acne. | 2006 Aug |
|
Demodex folliculorum and Demodex brevis as a cause of chronic marginal blepharitis. | 2007 |
|
[Determination of 12 sulfonamides in cosmetics by ultra performance liquid chromatography]. | 2007 Mar |
|
N-(2,6-Dimethyl-phen-yl)-2-methyl-acetamide. | 2008 Jan 9 |
|
Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model. | 2009 Aug |
|
Rosacea and its topical management. | 2009 Feb |
|
Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery. | 2010 |
|
Synthesis and biological activities of some novel triazoloquinazolines and triazinoquinazolines containing benzenesulfonamide moieties. | 2010 |
|
Curvularia keratomycosis in a dog. | 2010 Mar |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Patents
Sample Use Guides
Topical: apply a thin film to affected areas twice daily. Ophtalmic suspension/ointment: two drops of suspension should be instilled into the conjunctival sac every four hours during the day and at bedtime. A small amount, approximately 1/2 inch ribbon of ointment, should be applied in the conjunctival sac three or four times daily and once or twice at night.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6420538
P. aeruginosa, S. marcescens, St. epidermidis, C.
albicans, and A. fumigatus (spores) were exposed to two ophthalmic solutions each formulated with 10% sodium sulfacetamide and a preservative. Sulfacetamide solutions preserved with thimerosal have MIC values ranging from 0.2 to 2.8 for the five test microorganisms. The solutions preserved with parabens exhibit slightly higher MIC values for Pseudomonas, Serratia, and spores of Aspergillus (1.5-6.5) and significantly higher MIC values for Staphylococcus and Candida (19.6 and 5.0, respectively).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:07:52 GMT 2023
by
admin
on
Fri Dec 15 15:07:52 GMT 2023
|
Record UNII |
4NRT660KJQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29739
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6209-17-2
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
SUB04620MIG
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
6419954
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
DTXSID50211129
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
4NRT660KJQ
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
100000085048
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL455
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
SULFACETAMIDE SODIUM
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | Description: A white or yellowish white, crystalline powder; odourless. Solubility: Soluble in 1.5 parts of water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antiinfective agent. Storage: Sulfacetamide sodium should be kept in a well-closed container, protected from light. Additional information: Even in the absence of light, Sulfacetamide sodium is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Sulfacetamide sodium contains not less than 99.0% and not more than 101.0% of C8H9N2NaO3S, calculated with reference to the anhydrous substance. | ||
|
m10301
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
1624006
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
625324
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
9327
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
4NRT660KJQ
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
82101
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT000986
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
63858
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY | |||
|
C29467
Created by
admin on Fri Dec 15 15:07:52 GMT 2023 , Edited by admin on Fri Dec 15 15:07:52 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factor: for the calculation of the content, multiply the peak area of impurity A by 0.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |